Adv Clin Exp Med:模式识别受体的遗传多样性与过敏性疾病相关

2019-08-26 AlexYang MedSci原创

有证据显著编码模式识别受体(先天性免疫组分)基因的变异可能与特应性疾病相关。然而,结果仍旧是不确定的。最近,有研究人员确定了个体相关性和CD14(簇分化14)、TLR4 (toll样受体4)和TLR2 (toll样受体2)多态性互作对过敏性疾病可能的影响。研究包括了115名年龄在6到17岁的儿童。研究发现,3个多态性(CD14 C-159T、TLR4+896A/G和TLR2/-16934A/T)与

有证据显著编码模式识别受体(先天性免疫组分)基因的变异可能与特应性疾病相关。然而,结果仍旧是不确定的。

最近,有研究人员确定了个体相关性和CD14(簇分化14)、TLR4 (toll样受体4)和TLR2 (toll样受体2)多态性互作对过敏性疾病可能的影响。研究包括了115名年龄在6到17岁的儿童。研究发现,3个多态性(CD14 C-159T、TLR4+896A/G和TLR2/-16934A/T)与哮喘、过敏性鼻炎和特应性反应之间没有统计学显著的相关性。CD14/-159T和TLR2/-16934A等位基因杂合或者纯合的儿童的哮喘风险要比携带CD14的T等位基因而不携带TLR2A等位基因的儿童低4倍,比其他组哮喘的风险低3倍。考虑到过敏性鼻炎,研究人员观察到了相似的趋势。另外,TLR2/-16934中至少1 A等位基因的存在能够减少哮喘和过敏性鼻炎的风险,而TLR4+896多态性中只有常见的A等位基因纯和的儿童中哮喘和过敏性鼻炎风险减少。

最后,研究人员指出,他们的研究支持了CD14、TLR2和TLR4也许并不是直接的参与特应性疾病的发展。然而,他们的结果表明了这些多态性对哮喘和过敏性鼻炎的影响可能是通过基因互作来实现。

原始出处:

D?bińska A, Danielewicz H, Drabik-Chamerska A et al. Genetic polymorphisms in pattern recognition receptors are associated with allergic diseases through gene-gene interactions. Adv Clin Exp Med. 9 Aug 2019

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1648707, encodeId=f94b1648e075d, content=<a href='/topic/show?id=80a195082c4' target=_blank style='color:#2F92EE;'>#遗传多样性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95082, encryptionId=80a195082c4, topicName=遗传多样性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11f723650071, createdName=ay2008fy, createdTime=Thu Apr 30 07:09:00 CST 2020, time=2020-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047150, encodeId=7aa3204e15032, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Wed Nov 13 18:09:00 CST 2019, time=2019-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1470942, encodeId=7a2e14e0942a6, content=<a href='/topic/show?id=507043296fe' target=_blank style='color:#2F92EE;'>#多样性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43296, encryptionId=507043296fe, topicName=多样性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b6a7095267, createdName=neurosurgeon, createdTime=Wed Aug 28 12:09:00 CST 2019, time=2019-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609958, encodeId=63321609958bc, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Aug 28 12:09:00 CST 2019, time=2019-08-28, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1648707, encodeId=f94b1648e075d, content=<a href='/topic/show?id=80a195082c4' target=_blank style='color:#2F92EE;'>#遗传多样性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95082, encryptionId=80a195082c4, topicName=遗传多样性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11f723650071, createdName=ay2008fy, createdTime=Thu Apr 30 07:09:00 CST 2020, time=2020-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047150, encodeId=7aa3204e15032, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Wed Nov 13 18:09:00 CST 2019, time=2019-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1470942, encodeId=7a2e14e0942a6, content=<a href='/topic/show?id=507043296fe' target=_blank style='color:#2F92EE;'>#多样性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43296, encryptionId=507043296fe, topicName=多样性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b6a7095267, createdName=neurosurgeon, createdTime=Wed Aug 28 12:09:00 CST 2019, time=2019-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609958, encodeId=63321609958bc, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Aug 28 12:09:00 CST 2019, time=2019-08-28, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1648707, encodeId=f94b1648e075d, content=<a href='/topic/show?id=80a195082c4' target=_blank style='color:#2F92EE;'>#遗传多样性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95082, encryptionId=80a195082c4, topicName=遗传多样性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11f723650071, createdName=ay2008fy, createdTime=Thu Apr 30 07:09:00 CST 2020, time=2020-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047150, encodeId=7aa3204e15032, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Wed Nov 13 18:09:00 CST 2019, time=2019-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1470942, encodeId=7a2e14e0942a6, content=<a href='/topic/show?id=507043296fe' target=_blank style='color:#2F92EE;'>#多样性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43296, encryptionId=507043296fe, topicName=多样性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b6a7095267, createdName=neurosurgeon, createdTime=Wed Aug 28 12:09:00 CST 2019, time=2019-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609958, encodeId=63321609958bc, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Aug 28 12:09:00 CST 2019, time=2019-08-28, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1648707, encodeId=f94b1648e075d, content=<a href='/topic/show?id=80a195082c4' target=_blank style='color:#2F92EE;'>#遗传多样性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95082, encryptionId=80a195082c4, topicName=遗传多样性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11f723650071, createdName=ay2008fy, createdTime=Thu Apr 30 07:09:00 CST 2020, time=2020-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047150, encodeId=7aa3204e15032, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Wed Nov 13 18:09:00 CST 2019, time=2019-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1470942, encodeId=7a2e14e0942a6, content=<a href='/topic/show?id=507043296fe' target=_blank style='color:#2F92EE;'>#多样性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43296, encryptionId=507043296fe, topicName=多样性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b6a7095267, createdName=neurosurgeon, createdTime=Wed Aug 28 12:09:00 CST 2019, time=2019-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609958, encodeId=63321609958bc, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Aug 28 12:09:00 CST 2019, time=2019-08-28, status=1, ipAttribution=)]

相关资讯

Int Arch Allergy Immunol:RORA过表达能够减轻鼻粘膜损伤和增强红细胞免疫粘附功能

最近,有研究人员调查了是否RORA(维甲酸受体相关的孤儿受体α)能够减轻过敏性鼻炎(AR)的恶化。为了阐释RORA和RORTA与Wnt/β-catenin信号途径之间的调控机制可能产生的影响,研究人员建立了AR小鼠模型并利用RORA相关载体或者Wnt/β-catenin信号途径抑制剂WIF-1进行了相关处理。之后,研究人员测量了各种指标。研究发现,OVA诱导的AR小鼠模型表现出了明显的鼻粘膜损伤和

Int J Pediatr Otorhinolaryngol:过敏性鼻炎儿童患者呼出一氧化氮水平比较研究

最近,有研究人员确定了是否测量呼出一氧化氮(eNO)水平能够帮助区分过敏性鼻炎(AR)儿童和健康对照,并探究了是否AR与疾病严重度相关。研究包括了5-15岁的儿童,并分成了过敏性鼻炎组(n=40)和健康对照组(n=40)。研究进行的时间为2015年8月到2016年。研究人员根据ARIA分类将eNO水平与患者的临床疾病严重度进行了比较。研究发现,AR儿童中eNO水平(12.64±14.67ppb)要

Immunotherapy:MiR-146a类似物能够减轻过敏性鼻炎

最近,有研究人员调查了microRNA(miR)-146a在过敏性鼻炎(AR)中的治疗潜力情况。研究人员将雌性BALB/c小鼠随机分配到AR和miR-146a组。在第21-28天每天进行卵清蛋白(OVA)挑战之前,研究人员进行了鼻孔miR-146a给药。研究发现,miR-146a的表达水平在AR鼻粘膜中显著减少。miR-146a类似物能够显著的减轻打喷嚏和挠鼻事件,并减少卵清蛋白特异性lgE水平,

盘点:鼻炎疾病进展盘点

过敏性鼻炎主要由IgE介导的介质(主要是组胺)释放,并有多种免疫活性细胞和细胞因子等参与的鼻黏膜非感染性炎性疾病。其发生的必要条件有特异性抗原即引起机体免疫反应的物质、特应性个体、特异性抗原与特应型个体二者相遇。过敏性鼻炎是一个全球性健康问题,可导致许多疾病和劳动力丧失。梅斯医学小编整理了近期过敏性鼻炎的研究进展,与大家一起分享学习!【1】BMC Pediatr: 儿童中早期抗生素接触与哮喘和

盘点:鼻疾病与治疗进展

【1】Biosci Rep:金银花提取物能够减轻卵清蛋白诱导的过敏性鼻炎 https://www.ncbi.nlm.nih.gov/pubmed/31308153金银花具有抗病毒、抗氧化和抗炎症的特性。过敏性鼻炎(AR)是免疫球蛋白E(lgE)调控的炎症反应。最近,有研究人员调查了是否金银花提取物(HE)对AR具有治疗作用。研究发现,在AR模型中,HE不仅能够减少挠鼻和打喷嚏的次数,同时也能够

Laryngoscope:过敏性鼻炎中鼻流峰值可逆性与粘液纤毛清除关系研究

鼻减充血后利用鼻腔测压测量的鼻气流可逆性与过敏性炎症的严重度相关。峰值鼻气流是一种较为简单的评估鼻开放性的方法。最近,有研究人员评估了鼻减充血后鼻呼气和吸气流量峰值(PNEFs和PNIFs)变化与鼻粘膜纤毛清除时间(NMCCTs)的关系。研究是一个单中心的、前瞻性代表性研究,共包括了101名过敏性鼻炎患者。研究人员评估了鼻症状和NMMCCTs,并在减充血后进行了PNEF和PNIF测量。研究发现,在